News Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
18.75 ^USD	-1.57%		-1.16%	-13.75%

03-11	Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says	MT
03-11	RBC Cuts Price Target on Legend Biotech to $62 From $66, Keeps Outperform Rating	MT

All News

03-11	Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says	MT
03-11	RBC Cuts Price Target on Legend Biotech to $62 From $66, Keeps Outperform Rating	MT
03-10	Legend Biotech Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-10	Legend Biotech Corporation, Q4 2025 Earnings Call, Mar 10, 2026
03-10	Legend Biotech : LEGN Q4 2025 Slides 3.9.2026	PU
03-10	Legend Biotech Adjusted Q4 Earnings, Revenue Increase	MT
03-10	Earnings Flash (LEGN) Legend Biotech Corporation Reports Q4 Revenue $306.3M, vs. FactSet Est of $307.8M	MT
03-10	Earnings Flash (LEGN) Legend Biotech Corporation Posts Q4 Adjusted Net Income $0.01 per Share	MT
03-10	Earnings Flash (LEGN) Legend Biotech Posts Q4 Loss $0.08 a Share, vs. FactSet Est of $0.02 EPS	MT
03-10	Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights	GL
02-24	Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results	GL
02-23	Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion	RE
02-12	Legend Biotech Shares Lower After Rothschild & Co Redburn Downgrade	MT
02-12	Rothschild & Co Redburn Downgrades Legend Biotech to Neutral From Buy	MT
02-06	Legend Biotech Corporation Announces Board and Audit Committee Changes, Effective February 2, 2026	CI
01-23	Legend Biotech Corporation Announces Changes to Board of Directors and Audit Committee, Effective January 20, 2026	CI
01-22	TD Cowen Downgrades Legend Biotech to Hold From Buy, Adjusts Price Target to $21 From $62	MT
01-22	Genscript Biotech Associate Books $555 Million in Q4 CARVYKTI Sales	MT
01-21	Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use	GL
01-14	Legend Biotech Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:00 AM
01-14	Legend Biotech : 2026 JP Morgan Presentation - Legend Biotech	PU
01-12	Legend Biotech highlights recent business updates at 44th annual J.P. Morgan Healthcare conference	RE
01-12	Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference	GL
01-12	Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference	AQ
01-08	RBC Cuts Price Target on Legend Biotech to $66 From $74, Keeps Outperform Rating	MT